Etodolac

Research use only, not for human use.

A nonsteroidal anti-inflammatory drug that acts as a non-selective inhibitor of COX with IC50 of 53.5 nM.

A nonsteroidal anti-inflammatory drug that acts as a non-selective inhibitor of COX with IC50 of 53.5 nM; also inhibits PGHS-2 and shows 10-fold selectivity over PGHS-1; exhibits 10-fold selectivity for inhibition of PGHS-2 mediated TxB2 production in a human whole blood assay; Etodolac is licensed for the treatment of inflammation and pain caused by osteoarthritis and rheumatoid arthritis.Pain Approved(In Vitro):Post-marketing studies demonstrated that etodolac inhibition of cyclooxygenase is somewhat COX-2 selective similar to celecoxib and other "COX-2 inhibitors." Unlike rofecoxib, both etodolac and celecoxib can fully inhibit COX-1 and are designated as having "preferential selectivity" toward COX-2. The (inactive against COX) r-enantiomer of etodolac inhibits beta-catenin levels in hepatoma cells.

Post-marketing studies demonstrated that etodolac inhibition of cyclooxygenase is somewhat COX-2 selective similar to celecoxib and other "COX-2 inhibitors." Unlike rofecoxib, both etodolac and celecoxib can fully inhibit COX-1 and are designated as having "preferential selectivity" toward COX-2. The (inactive against COX) r-enantiomer of etodolac inhibits beta-catenin levels in hepatoma cells.

——

AY 24236 | (±)-Etodolac | NIH 9918 | NSC 282126

Chromatin/Epigenetic

COX

COX|RXR-alpha

Neurological Disease

Pain

41340-25-4

287.3535

C17H21NO3

>98% (HPLC)

10 mM in DMSO

O=C(O)CC1(CC)OCCC2=C1NC3=C2C=CC=C3CC

Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-

(-20℃)

With Ice Pack

≥ 2 years